- Home
- ATXG vs GLTO Comparison
ATXG vs GLTO Comparison
Compare ATXG & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATXG
- GLTO
- Stock Information
- Founded
- ATXG 2014
- GLTO 2011
- Country
- ATXG China
- GLTO Denmark
- Employees
- ATXG N/A
- GLTO N/A
- Industry
- ATXG Professional Services
- GLTO Biotechnology: Pharmaceutical Preparations
- Sector
- ATXG Consumer Discretionary
- GLTO Health Care
- Exchange
- ATXG Nasdaq
- GLTO Nasdaq
- Market Cap
- ATXG 4.0M
- GLTO 4.5M
- IPO Year
- ATXG N/A
- GLTO 2020
- Fundamental
- Price
- ATXG $0.70
- GLTO $3.52
- Analyst Decision
- ATXG
- GLTO Buy
- Analyst Count
- ATXG 0
- GLTO 1
- Target Price
- ATXG N/A
- GLTO $10.00
- AVG Volume (30 Days)
- ATXG 2.4M
- GLTO 23.9K
- Earning Date
- ATXG 08-13-2025
- GLTO 08-11-2025
- Dividend Yield
- ATXG N/A
- GLTO N/A
- EPS Growth
- ATXG N/A
- GLTO N/A
- EPS
- ATXG N/A
- GLTO N/A
- Revenue
- ATXG $4,180,913.00
- GLTO N/A
- Revenue This Year
- ATXG N/A
- GLTO N/A
- Revenue Next Year
- ATXG N/A
- GLTO N/A
- P/E Ratio
- ATXG N/A
- GLTO N/A
- Revenue Growth
- ATXG N/A
- GLTO N/A
- 52 Week Low
- ATXG $0.49
- GLTO $2.01
- 52 Week High
- ATXG $1.86
- GLTO $15.13
- Technical
- Relative Strength Index (RSI)
- ATXG 57.52
- GLTO 57.89
- Support Level
- ATXG $0.62
- GLTO $3.50
- Resistance Level
- ATXG $0.74
- GLTO $4.10
- Average True Range (ATR)
- ATXG 0.09
- GLTO 0.31
- MACD
- ATXG 0.01
- GLTO 0.01
- Stochastic Oscillator
- ATXG 35.20
- GLTO 55.00
About ATXG Addentax Group Corp.
Addentax Group Corp is an investment holding company. The company through its operating subsidiaries functions in the following segments; Garment manufacturing; Logistics services; Property management and subleasing. It generates maximum revenue from the Logistics services segment which provides logistics services including storage, transportation, warehousing, handling, packaging, and order processing. It also provides customs declaration and tax clearance services to its customers who export goods overseas. Geographically, the company derives all of its revenue from China.
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.